IJR News — today's news from every side

IJR News — today's news from every side

blockversewordysbillionaire.aiyourlistWhiteboardAppquizieunschool

Loading

Want your own hosted, self-optimizing clone of this — or any OpenServe site? Open Development for enterprise →

© OpenServe Holdings LLC

Privacy Notice Data rights Terms of Service Feedback Cookie NoticeHelp Acceptable Use Copyright AI Notice Your Privacy Choices Subprocessors Data Processing Addendum Installed App Terms Company Solutions Free assessment Investors Get the app Contact

News

Home
Politics
World
Sports
Markets
Business
Entertainment
Music
Health
Tech
Science
Good News
Encouragement
Video
Meme Wars

Brands

Yourlist
Quizie
FaithTap
Blessed
All brands

US Public Gets Look at B-21 Raider, Powerful Aircraft Will Soon Begin To Replace Iconic American BombersReporting — Jul 11, 2021The Air Force has given the public its first glimpse at a new bomber that will replace two pieces of America’s bombing fleet. The new bomber, which was developed to replace the B-1 and B-2 bombers, is dubbed the B-21…

ImmuPharma Selects Thermo Fisher CDMO for Kapiglucagon — Jul 22, 2026ImmuPharma has named Thermo Fisher Scientific’s Patheon as the drug product CDMO for Kapiglucagon, following the earlier selection of Bachem for API manufacturing, as it pushes the glucagon prodrug toward IND-enabling development for Type 1 diabetes and potential dual-hormone artificial pancreas applications. The company is pursuing a streamlined regulatory path, potentially a 505(b)(2) in the U.S., with plans to file an IND and begin first-in-human studies subject to regulatory confirmation.

Monvia Begins ASX Trading After $17.5M IPO — Jul 22, 2026Monvia outlined its post-listing shareholder base, noting 295 registered holders with a custodian arrangement that can mask underlying investors, and highlighted governance groundwork including a Board Charter and a Remuneration and Nomination Committee ahead of ASX listing. It also disclosed a fully underwritten 17.5 million capital raise via a replacement prospectus, with capital allocated for strategic initiatives and the redemption of Series B Preference Shares, culminating in ASX admission on 22 July 2026 and trading from 24 July under the ticker MNV.